Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells

Claim 2

A process for forming longitudinally oriented neo-vascular capillaries, said process comprising the steps of: (a) providing a combination ultra-thin film (UTF) pattern of at least one cell adhesion promoter and at least one cell adhesion inhibitor wherein said cell adhesion promoters have a linewidth of between about 50-490 μm; (b) seeding said combination UTF pattern with cells capable of forming capillaries at an initial seeding cell density; (c) adding a first medium for incubating said seeded cells until said cells are grown to confluency, wherein said first medium is a medium for promoting cell growth; (d) replacing said first medium with a second medium at confluency, wherein said second medium is a medium for promoting cell differentiation; and (e) allowing said cells to differentiate into spatially oriented neo-vascular capillaries oriented parallel to said UTF pattern of said at least one cell adhesion promoter.

Claim 3

The process of claim 1 wherein said step (a) of providing further comprises: (f) coating a substrate having a first exposed surface with a compound to obtain an ultra-thin film (UTF) which is reactive to radiation and has a second exposed surface of at least one cell adhesion promoter or cell adhesion inhibitor; (g) irradiating said second exposed surface of said UTF in a pattern having one or more lines having linewidths between about 50-490 μm to obtain an irradiated film in which a fraction of said cell adhesion promoters or said cell adhesion inhibitors have been removed to reexpose said first exposed surface; and (h) treating said irradiated film with a second compound to bind to said reexposed surface in which at least a fraction of said cell adhesion promoter or cell adhesion inhibitor has been removed to form said combination UTF pattern.

Claim 4

The process of claim 2, wherein said cell adhesion promoter is selected from the group consisting of: N-(2-aminoethyl-3-aminopropyl)-trimethoxysilane (EDA), 11-aminoundecyltrimethoxysilane, 3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane, 3-aminopropylmethyldiethoxysilane, 3-aminopropyldimethylethoxysilane, 3-(1-aminopropoxy)-3,3-dimethyl-1-propenyltrimethoxysilane, N-(2-aminoethyl)-3-aminopropylmethyldimethoxysilane, bis(3-(trimethoxysilyl)propyl)ethylenediamine, trimethoxysilylpropyldiethylenetriamene, (aminoethylaminomethyl)phenethyltrimethoxysilane (DAP), isopropyltri-(n-ethyledenediamino)-ethyltitanate, neopentyl-(dialiyl)-oxytri-(n-ethylenediamino)-ethyltitanate, neopentyl-(dialiyl)-oxytri-(n-amino)-phenyltitanate, neopentyl-(dialiyl)-oxytri-(n-ethylenediamino)-ethylzirconate, neopentyl-(dialiyl)-oxytri-(n-amino)-phenylzirconate, a peptide of the sequence GLY-ARG-GLY-ASP-TYR (SEQ ID NO:1), and a peptide of the sequence GLY-TYR-ILE-GLY-SER-ARG-TYR (SEQ ID NO:2) and mixtures thereof; wherein said cell adhesion inhibitor is selected from the group consisting of: tridecafluoro-(1,1,2,2-tetrahydrooctyl)-1-diemethylchlorosilane (13F), tridecafluoro-(1,1,2,2-tetrahydrooctyl)-1-methyldichlorosilane, tridecafluoro-(1,1,2,2-tetrahydrooctyl)-1-triethoxysilane, (3,3,3-trifluoropropyl)-trichlorosilane, (3,3,3-trifluoropropyl)-methyldichlorosilane, (3,3,3-trifluoropropyl)-dimethylchlorosilane, (3,3,3-trifluoropropyl)-methyldimethoxysilane, (3,3,3-trifluoropropyl)-trimethoxysilane, (heptafluoroisopropoxy)-propylmethyldichlorosilane, (3-pentafluorophenylpropyl)-dimethylchlorosialne (PFP), 3-glycidoxypropyltrimethoxysilane, and mixtures thereof; wherein said substrate is selected from the group consisting of: quartz silica, glass silica, silicon, germanium, gallium arsenide, epoxy resins, polysytrenes, polysulfones, aluminum, platinum, alumina, silicones, rubber, fluoropolymers, polyesters, acrylic copolymers, polygalactin, polyacetates, polyglycolic acids, polylactic acids, hydroxyapatite, ceramics, and mixtures thereof; and wherein said cells are HUVECs.

Claim 5

The process of claim 3, wherein said first medium further comprises M-199, serum, ECGF and BBE; wherein said first medium is replaced with fresh first medium at least every other day; wherein said second medium further comprises M-199, serum and b-FGF and does not contain ECGF and does not contain BBE; and wherein said second medium is replaced with fresh second medium at least every other day.

Claim 6

The process of claim 4, wherein said linewidth of said cell adhesion promoters is between about 65-40.0 μm.

Claim 7

The process of claim 5, wherein said linewidth of said cell adhesion promoters is between about 70-350 μm.

Claim 8

The process of claim 6, wherein said linewidth of said cell adhesion promoters is between about 75-300 μm.

Claim 9

The process of claim 7, wherein said linewidth of said cell adhesion promoters is between about 80-250 μm.

Claim 10

The process of claim 8, wherein said linewidth of said cell adhesion promoters is between about 85-200 μm.

Claim 11

The process of claim 9, wherein said linewidth of said cell adhesion promoters is between about 90-150 μm.

Claim 12

The process of claim 10, wherein said linewidth of said cell adhesion promoters is between about 95-100 μm.

Claim 13

The process of claim 2, wherein said cell adhesion promoter is selected from the group consisting of: N-(2-aminoethyl-3-aminopropyl)-trimethoxysilane (EDA), 11-aminoundecyltrimethoxysilane, 3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane, 3-aminopropylmethyldiethoxysilane, 3-aminopropyldimethylethoxysilane, 3-(1-aminopropoxy)-3,3-dimethyl-1-propenyltrimethoxysilane, N-(2-aminoethyl)-3-aminopropylmethyldimethoxysilane, bis(3-(trimethoxysilyl)propyl)ethylenediamine, trimethoxysilylpropyldiethylene-triamene, (aminoethylaminomethyl)phenethyltrimethoxysilane (DAP), isopropyltri-(n-ethylenediamino)-ethyltitanate, neopentyl-(dialiyl)-oxytri-(n-ethylenediamino)-ethyltitanate, neopentyl-(dialiyl)-oxytri-(n-amino)-phenyltitanate, neopentyl-(dialiyl)-oxytri-(n-ethylenediamino)-ethylzirconate, neopentyl-(dialiyl)-oxytri-(n-amino)-phenylzirconate, a peptide of the sequence GLY-ARG-GLY-ASP-TYR (SEQ ID NO:1), and a peptide of the sequence GLY-TYR-ILE-GLY-SER-ARG-TYR (SEQ ID NO:2) and mixtures thereof; wherein said cell adhesion inhibitor is selected from the group consisting of: tridecafluoro-(1,1,2,2-tetrahydrooctyl)-1-diemethylchlorosilane (13F), tridecafluoro-(1,1,2,2-tetrahydrooctyl)-1-methyldichlorosilane, tridecafluoro-(1,1,2,2-tetrahydrooctyl)-1-triethoxysilane, (3,3,3-trifluoropropyl)-trichlorosilane, (3,3,3-trifluoropropyl)-methyldichlorosilane, (3,3,3-trifluoropropyl)-dimethylchlorosilane, (3,3,3-trifluoropropyl)-methyldimethoxysilane, (3,3,3-trifluoropropyl)-trimethoxysilane, (heptafluoroisopropoxy)-propylmethyldichlorosilane, (3-pentafluorophenylpropyl)-dimethylchlorosialne (PFP), 3-glycidoxypropyltrimethoxysilane, and mixtures thereof; wherein said substrate is selected from the group consisting of: quartz silica, glass silica, silicon, germanium, gallium arsenide, epoxy resins, polysytrenes, polysulfones, aluminum, platinum, alumina, silicones, rubber, fluoropolymers, polyesters, acrylic copolymers, polygalactin, polyacetates, polyglycolic acids, polylactic acids, hydroxyapatite, ceramics, and mixtures thereof; and wherein said cells are PCMVECs.

Claim 14

The process of claim 12, wherein said first medium further comprises M-199, serum, and BBE; wherein said first medium is replaced with fresh first medium at least every other day; wherein said second medium further comprises M-199, serum and does not contain retinal extract; and wherein said second medium is replaced with fresh second medium at least every other day.

Claim 15

The process of claim 13, wherein said linewidth of said cell adhesion promoters is between about 65-400 μm.

Claim 16

The process of claim 14, wherein said linewidth of said cell adhesion promoters is between about 70-350 μm.

Claim 17

The process of claim 15, wherein said linewidth of said cell adhesion promoters is between about 75-300 μm.

Claim 18

The process of claim 16, wherein said linewidth of said cell adhesion promoters is between about 80-250 μm.

Claim 19

The process of claim 17, wherein said linewidth of said cell adhesion promoters is between about 85-200 μm.

Claim 20

The process of claim 18, wherein said linewidth of said cell adhesion promoters is between about 90-150 μm.

Claim 21

The process of claim 19, wherein said linewidth of said cell adhesion promoters is between about 95-100 μm.

Claim 22

The process of claim 1 wherein said cell adhesion promoter is an aminosilane; and wherein said cell adhesion inhibitor is a fluorosilane.

Claim 23

The process of claim 1 wherein said cells are selected from the group consisting of primary micro-vascular endothelial cells, primary vascular endothelial cells, transformed cells of endothelial origin and mixtures thereof.

Claim 24

The process of claim 1, wherein said first medium contains a cell growth agent and is essentially free of cell differentiation agent, and wherein said second medium contains cell differentiation agent.

Claim 25

The process of claim 1, wherein said cells are endothelial cells.